Additionally, using a mouse glioma model, dual treatments with anti-TIM-3 antibody and either stereotactic radiosurgery (SRS) or anti-PD-1 were shown to improve survival of the tumour-bearing animals compared with anti-TIM-3 alone; triple therapy also resulted in a significant survival improvement compared to either dual therapy [28]. This evidence concerns the gene HAVCR2 and glioma.